Blogs

Symphogen

Region: Denmark
Version: Liferay Portal 5.2

Symphogen is the leader in developing recombinant polyclonal antibodies (rpAb), a new class of biopharmaceuticals for the treatment or prophylaxis of serious human diseases. By employing its pioneering antibody discovery and manufacturing technologies, Symphogen generates recombinant antibody compositions that capture the diversity and effectiveness of the natural immune system. Symphogen’s pipeline of product candidates and development programs address large and growing markets, such as the replacement of plasma-derived immunoglobulins, oncology, and a broad range of infectious diseases.